RATIO-PENTOXIFYLLINE TABLET (EXTENDED-RELEASE)
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
18-09-2009
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
PENTOXIFYLLINE
Beschikbaar vanaf:
RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
ATC-code:
C04AD03
INN (Algemene Internationale Benaming):
PENTOXIFYLLINE
Dosering:
400MG
farmaceutische vorm:
TABLET (EXTENDED-RELEASE)
Samenstelling:
PENTOXIFYLLINE 400MG
Toedieningsweg:
ORAL
Eenheden in pakket:
60/100/500TABS
Prescription-type:
Prescription
Therapeutisch gebied:
HEMORRHEOLOGIC AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0115837001; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2010-08-02
Productkenmerken
PRODUCT MONOGRAPH
Pr
ratio-PENTOXIFYLLINE
(pentoxifylline)
400 mg Sustained-Release Tablets
Vasoactive agent
ratiopharm inc.
17800, rue Lapointe
Mirabel (Québec)
Canada, J7J 1P3
Date of Revision:
September 18, 2009
Submission Control No: 131604
_ _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................. 3
SUMMARY
PRODUCT
INFORMATION........................................................ 3
INDICATIONS
AND
CLINICAL
USE ............................................................. 3
CONTRAINDICATIONS
..................................................................................
3
WARNINGS
AND
PRECAUTIONS
................................................................. 4
ADVERSE
REACTIONS...................................................................................
5
DRUG
INTERACTIONS
...................................................................................
6
DOSAGE
AND
ADMINISTRATION
............................................................... 8
OVERDOSAGE
.................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY.............................................. 8
STORAGE
AND
STABILITY
...........................................................................
9
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ............................... 9
PART II: SCIENTIFIC INFORMATION
....................................................... 10
PHARMACEUTICAL
INFORMATION.........................................................
10
DETAILED
PHARMACOLOGY
....................................................................
11
TOXICOLOGY
................................................................................................
13
REFERENCES
.................................................................................................
17
PART III: CONSUMER
INFORMATION...................................................... 19
_ _
_ _
_ _
_Page 3 of 20_
P
ratio-PENTOXIFYLLINE
(pentoxifylli
Lees het volledige document
